Alendronic acid
- Generic Name
- Alendronic acid
- Brand Names
- Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
- Drug Type
- Small Molecule
- Chemical Formula
- C4H13NO7P2
- CAS Number
- 66376-36-1
- Unique Ingredient Identifier
- X1J18R4W8P
- Background
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
- Associated Conditions
- Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease
- Associated Therapies
- -
Precision Medicine Approach for Osteoporosis - Follow Up Study
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Hartmut Malluche, MD
- Target Recruit Count
- 40
- Registration Number
- NCT06264609
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Denosumab vs Alendronate After Vertebroplasty
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05662358
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
Efficacy and Safety of Minodronate in Patients With Low Back Pain
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT05645289
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 170
- Registration Number
- NCT05387200
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Hartmut Malluche, MD
- Target Recruit Count
- 60
- Registration Number
- NCT05151484
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
The Optimal Sequential Therapy After Long Term Denosumab Treatment
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT05091099
- Locations
- 🇨🇳
National Taiwan University Hospital, Yunlin branch, Douliu, Yunlin County, Taiwan
Romosozumab in Women With Chronic SCI
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 12
- Registration Number
- NCT04708886
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 90
- Registration Number
- NCT03692143
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT03623633
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 24
- Registration Number
- NCT03396315
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Creighton University, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.